NCT06478407 Community Screening Study of Diabetic Retinopathy in Tianjin in 2024
| NCT ID | NCT06478407 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Li Xiaorong |
| Condition | Diabetic Retinopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 18,000 participants |
| Start Date | 2024-03-28 |
| Primary Completion | 2025-03-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 18,000 participants in total. It began in 2024-03-28 with a primary completion date of 2025-03-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Through this study, the investigators hope to understand the prevalence and influencing factors of diabetic retinopathy in Tianjin, improve the ability of complication detection and intervention in diabetic patients in primary medical and health institutions, and build a diabetes prevention and treatment network. The investigators should adhere to the policy of prevention first, combined with prevention and control, and explore a diabetes' prevention and control model suitable for our city. Extensive publicity and education should be carried out to improve the awareness of self-management ，improve the screening rate of diabetic retinopathy, and reduce the blindness rate.
Eligibility Criteria
Inclusion Criteria: \- 1: Clear awareness, barrier-free communication 2: diabetes Exclusion Criteria: * 1: Have left the registered home address 2: In the last 6 months, you have not lived in your place of residence 3: Have a serious mental illness
Contact & Investigator
Xiaorong Li, professor
PRINCIPAL INVESTIGATOR
Tianjin Medical University Eye Hospital
Frequently Asked Questions
Who can join the NCT06478407 clinical trial?
This trial is open to participants of all sexes, studying Diabetic Retinopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06478407 currently recruiting?
Yes, NCT06478407 is actively recruiting participants. Contact the research team at tydljp@126.com for enrollment information.
Where is the NCT06478407 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT06478407 clinical trial?
NCT06478407 is sponsored by Li Xiaorong. The principal investigator is Xiaorong Li, professor at Tianjin Medical University Eye Hospital. The trial plans to enroll 18,000 participants.